324 related articles for article (PubMed ID: 23722191)
21. Lichenoid drug eruption with hyperpigmentation caused by imatinib mesylate.
Kagimoto Y; Mizuashi M; Kikuchi K; Aiba S
Int J Dermatol; 2014 Mar; 53(3):e161-2. PubMed ID: 23786260
[No Abstract] [Full Text] [Related]
22. Challenges in oncology. Case 3. Depigmentation in a chronic myeloid leukemia patient treated with STI-571.
Raanani P; Goldman JM; Ben-Bassat I
J Clin Oncol; 2002 Feb; 20(3):869-70. PubMed ID: 11821474
[No Abstract] [Full Text] [Related]
23. Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate.
Rousselot P; Larghero J; Raffoux E; Calvo F; Tulliez M; Giraudier S; Rybojad M
Br J Haematol; 2003 Mar; 120(6):1091-2. PubMed ID: 12648085
[No Abstract] [Full Text] [Related]
24. Unusual extramedullary relapses under imatinib mesylate treatment in chronic myeloid leukemia.
Beyazit Y; Aksu S; Kekilli M; Haznedaroglu IC; Kilickap S; Goker H
Am J Hematol; 2005 May; 79(1):79-80. PubMed ID: 15849758
[No Abstract] [Full Text] [Related]
25. Uncommon syndromes and treatment manifestations of malignancy: Case 4. Periorbital edema and imatinib mesylate therapy for chronic myelogenous leukemia.
Ramar K; Potti A; Mehdi SA
J Clin Oncol; 2003 Jan; 21(1):172-3. PubMed ID: 12506189
[No Abstract] [Full Text] [Related]
26. Early imatinib-mesylate-induced hepatotoxicity in chronic myelogenous leukaemia.
Kong JH; Yoo SH; Lee KE; Nam SH; Kwon JM; Lee SM; Chang HJ; Choi MY; Cho MS; Mun YC; Nam E; Lee SN; Seong CM
Acta Haematol; 2007; 118(4):205-8. PubMed ID: 18030002
[TBL] [Abstract][Full Text] [Related]
27. Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate.
Arora B; Kumar L; Sharma A; Wadhwa J; Kochupillai V
Ann Oncol; 2004 Feb; 15(2):358-9. PubMed ID: 14760137
[No Abstract] [Full Text] [Related]
28. [Additional chromosomal abnormalities in dynamic of target therapy for chronic myeloid leukemia in children and adolescents].
Andreeva SV; Drozdova VD
Lik Sprava; 2014; (1-2):55-9. PubMed ID: 24908961
[TBL] [Abstract][Full Text] [Related]
29. Vitiligo-like lesions in an adult patient treated with Imatinib mesylate.
Cerchione C; Fabbricini R; Pane F; Luciano L
Leuk Res; 2009 Aug; 33(8):e104-5. PubMed ID: 19232719
[No Abstract] [Full Text] [Related]
30. Successful management of liver injury caused by imatinib mesylate in a patient with previously untreated chronic myelogenous leukemia in the chronic phase.
Yamazaki R; Okamoto S; Chen CK; Tada S; Saito H; Shibata R; Sakamoto M; Mori T; Ikeda Y
Leuk Lymphoma; 2006 Jul; 47(7):1427-30. PubMed ID: 16923586
[No Abstract] [Full Text] [Related]
31. Imatinib-induced erythrodermia in a patient with chronic myeloid leukemia.
Oztas P; Erbasi S; Lenk N; Polat M; Han O; Artuz F; Alli N
Acta Derm Venereol; 2006; 86(2):174-5. PubMed ID: 16648930
[No Abstract] [Full Text] [Related]
32. Hypersensitivity pneumonitis related to imatinib mesylate.
Bergeron A; Bergot E; Vilela G; Ades L; Devergie A; Espérou H; Socié G; Calvo F; Gluckman E; Ribaud P; Rousselot P; Tazi A
J Clin Oncol; 2002 Oct; 20(20):4271-2. PubMed ID: 12377975
[No Abstract] [Full Text] [Related]
33. Hyperpigmentation of the hard palate associated with imatinib therapy for chronic myeloid leukemia with a genetic variation in the proto-oncogene c-KIT.
Khoo TL; Catalano A; Supple S; Chong L; Yeoh SC; Yeung S; Iland H
Leuk Lymphoma; 2013 Jan; 54(1):186-8. PubMed ID: 22712835
[No Abstract] [Full Text] [Related]
34. Exacerbation of psoriasis in a chronic myelogenous leukemia patient treated with imatinib.
Woo SM; Huh CH; Park KC; Youn SW
J Dermatol; 2007 Oct; 34(10):724-6. PubMed ID: 17908148
[No Abstract] [Full Text] [Related]
35. Imatinib-induced optic neuritis in a patient of chronic myeloid leukemia.
Govind Babu K; Attili VS; Bapsy PP; Anupama G
Int Ophthalmol; 2007 Feb; 27(1):43-4. PubMed ID: 17410337
[TBL] [Abstract][Full Text] [Related]
36. Sustained complete cytogenetic remission in a patient with chronic myeloid leukemia after discontinuation of imatinib mesylate therapy.
Okabe S; Tauchi T; Ishii Y; Akahane D; Nunoda K; Honda S; Takaku T; Ohyashiki K
Int J Hematol; 2007 Feb; 85(2):173-4. PubMed ID: 17321998
[No Abstract] [Full Text] [Related]
37. The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia.
Eskazan AE; Elverdi T; Yalniz FF; Salihoglu A; Ar MC; Ongoren Aydin S; Baslar Z; Aydin Y; Tuzuner N; Ozbek U; Soysal T
Leuk Lymphoma; 2014 Dec; 55(12):2935-7. PubMed ID: 24650055
[No Abstract] [Full Text] [Related]
38. Oral and cutaneous lichenoid reaction with nail changes secondary to imatinib: report of a case and literature review.
Wahiduzzaman M; Pubalan M
Dermatol Online J; 2008 Dec; 14(12):14. PubMed ID: 19265627
[TBL] [Abstract][Full Text] [Related]
39. Imatinib mesylate-induced neutrophilic folliculitis in a teenager.
García-Romero MT; Durán-McKinster C; de Ocariz MS; Carrasco-Daza D; Palacios-López C; Orozco-Covarrubias L; Ruiz-Maldonado R
Int J Dermatol; 2012 Dec; 51(12):1529-30. PubMed ID: 22486540
[No Abstract] [Full Text] [Related]
40. Imatinib-induced nail hyperpigmentation in chronic myeloid leukemia.
Prabhash K; Biswas G; Prasad N; Karant N; Sastry PS; Parikh PM
Indian J Dermatol Venereol Leprol; 2006; 72(1):63-4. PubMed ID: 16481719
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
